Less than 25 percent of patients newly diagnosed with acute myeloid leukemia (AML) survive beyond five years. The disease causes more than 10,000 deaths a year in the U.S., and treatment options have remained largely unchanged in 30 years.
In 2013, OHSU’s Knight Cancer Institute teamed up with The Leukemia & Lymphoma Society to find a path to treatment for this complex form of leukemia. Their research initiative, Beat AML, brought together nine drug companies and six universities to collaboratively zero in on potential drivers of the disease. They did so by sequencing cancer cell DNA from hundreds of patients who volunteered samples. In the past two years, the project has generated a number of treatment ideas and supplied a stock of drug candidates. Beat AML findings were presented on Dec. 5-8 at the American Society of Hematology Annual Meeting in Orlando, FL. Learn more here about these findings and see which OHSU researchers have made significant contributions.